Glenmark Pharmaceuticals Limited Share Price and Company Fundamentals
Last traded: Today at 9:45 AM
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab and ISB 830-X8, a OX40 antagonist mAb for the treatment of atopic dermatitis. In addition, the company offers Ryaltris, fixed-dose nasal spray for the treatment of allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Key Metrics
PE ratio
35.31
PB ratio
6.03
Dividend yield
0.33%
Beta
0.25
Market cap
₹634.02B
Enterprise value
₹628.24B
Company profile
| Industry / Sector | Drug Manufacturers - Specialty & Generic / Healthcare |
|---|---|
| Full time employees | 16946 |
| Website | https://glenmarkpharma.com |
| Mailing address | Glenmark House B.D. Sawant Marg Chakala, Off Western Express Highway Andheri (East) Mumbai 400099 India |
| Phone / Fax | 91 22 4018 9999 / 91 22 4018 9986 |
Dividends
Dividend yield
0.33%
Dividend amount
₹7.50
Payout ratio
7.85%
5Y Avg. yield
-%
Glenmark Pharmaceuticals Limited paid ₹7.50 dividend and the ex-dividend date was 31 Aug 2026.The dividend payout ratio is 7.85%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.GLENMARK dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Aug 2026, following are the company executives and directors listed on Glenmark Pharmaceuticals Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Glenn Mario Saldanha | Chairman, MD & CEO | 55 | |
| Mr. Utkarsh Gandhi | Senior General Manager of Investor Relations | ||
| Mr. Samir Salauddin Kazi | Executive VP & Head of Legal, Compliance & Intellectual Property | 50 | |
| Ms. Rashmi Khandelwal | Company Secretary & Compliance Officer | ||
| Ms. Shweta Munjal | Chief Communications & CSR Officer | ||
| Mr. P. Chinnapa Reddy | Executive Vice President and Global Head Business Development | 53 | |
| Dr. Joseph O'Sullivan | VP and Head of Global Business Development & Licensing - Innovative Therapeutics | ||
| Dr. Michael Koslowski | Chief Medical Officer | ||
| Mr. K. Yamdagni Vipul | Senior Vice President | ||
| Mr. Edsel Pereira | EVP of Information Technology |
Profitability and management effectiveness
Profit margin
10.14%
Operating margin
15.72%
Return on assets
-
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Glenmark Pharmaceuticals Limited is 634.02B and its enterprise value is 628.24B. The enterprise value to revenue ratio of GLENMARK is 3.54. The enterprise value to EBITDA ratio of GLENMARK is 13.00.
The GLENMARK's stocks Beta value is 0.25 making it 75% less volatile compared to NSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Frequently Asked Questions
1. What is Glenmark Pharmaceuticals Limited's Stock Symbol?
Glenmark Pharmaceuticals Limited trades on NSE under the ticker symbol "GLENMARK".
2. What is Glenmark Pharmaceuticals Limited's stock price today?
One share of GLENMARK stock can currently be purchased for approximately ₹2246.5.
3. How can I contact Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited's mailing address is Glenmark House B.D. Sawant Marg Chakala, Off Western Express Highway Andheri (East) Mumbai 400099 India. The company can be reached via phone at 91 22 4018 9999.
4. What is Glenmark Pharmaceuticals Limited's official website?
The official website of Glenmark Pharmaceuticals Limited is https://glenmarkpharma.com.